Future Science Group
PHENIX_revised_supplement_15SEP2021_TRACKED.docx (116.69 kB)

FON-2021-0886 Supplementary Data

Download (116.69 kB)
posted on 2021-10-15, 09:54 authored by Oliver Sartor, Daniel George, Bertrand Tombal, Neeraj Agarwal, Celestia S. Higano, Cora N. Sternberg, Kurt Miller, XiaoLong Jiao, Helen Guo, Per Sandström, Amanda Bruno, Frank Verholen, Fred Saad, Neal Shore

Supplemental Figure 1. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC

Kaplan–Meier curves of time to first SSE after the start of second-line therapy. (A) Radium-223 cohort. (B) Alternative NHT cohort.

CI, Confidence interval; NE, Not estimable; NHT, Novel hormonal therapy; SSE, Symptomatic skeletal event.


Bayer HealthCare